These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 30981)

  • 1. Potentiation of apomorphine action in rats by l-prolyl-l-leucyl-glycine amide.
    Kostrzewa RM; Kastin AJ; Sobrian SK
    Pharmacol Biochem Behav; 1978 Sep; 9(3):375-8. PubMed ID: 30981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of L-prolyl-L-leucyl-glycine amide (MIF-I) on dopaminergic neurons.
    Kostrzewa RM; Spirtes MA; Klara JW; Christensen CW; Kastin AJ; Joh TH
    Pharmacol Biochem Behav; 1976; 5(Suppl 1):125-7. PubMed ID: 13412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of prolyl-leucyl-glycine amide on drug-induced rotation in lesioned rats.
    Smith JR; Morgan M
    Gen Pharmacol; 1982; 13(3):203-7. PubMed ID: 6124481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of dopaminergic neurotransmission in the 6-hydroxydopamine lesioned rotational model by peptidomimetic analogues of L-prolyl-L-leucyl-glycinamide.
    Ott MC; Mishra RK; Johnson RL
    Brain Res; 1996 Oct; 737(1-2):287-91. PubMed ID: 8930377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MIF-I and postsynaptic receptor sites for dopamine.
    Kostrzewa RM; Hardin JC; Snell RL; Kastin AJ; Coy DH; Bymaster F
    Brain Res Bull; 1979; 4(5):657-62. PubMed ID: 39665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of apomorphine-induced stereotypies by naloxone and L-prolyl-L-leucyl-glycinamide.
    Quock RM; Lucas TS; Hartl TJ
    Pharmacol Biochem Behav; 1983 Jul; 19(1):49-52. PubMed ID: 6137836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolyl-leucyl-glycine amide (PLG) and thyrotropin-releasing hormone (TRH): DOPA potentiation and biogenic amine studies.
    Plotnikoff NP
    Prog Brain Res; 1975; 42():11-23. PubMed ID: 730
    [No Abstract]   [Full Text] [Related]  

  • 8. Striatal dopamine turnover and MIF-I.
    Kostrzewa RM; Fukushima H; Harston CT; Perry KW; Fuller RW; Kastin AJ
    Brain Res Bull; 1979; 4(6):799-802. PubMed ID: 43187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of L-prolyl-L-leucyl glycinamide with dopamine D2 receptor: evidence for modulation of agonist affinity states in bovine striatal membranes.
    Srivastava LK; Bajwa SB; Johnson RL; Mishra RK
    J Neurochem; 1988 Mar; 50(3):960-8. PubMed ID: 2892892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MIF-1 attenuates apomorphine stereotypies in adult rats after neonatal 6-hydroxydopamine.
    Kostrzewa RM; White TG; Zadina JE; Kastin AJ
    Eur J Pharmacol; 1989 Apr; 163(1):33-42. PubMed ID: 2568266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings.
    Chiu S; Paulose CS; Mishra RK
    Peptides; 1981; 2(1):105-11. PubMed ID: 6113579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological studies with a tripeptide, prolyl-leucyl glycine amide.
    Plotnikoff NP; Kastin AJ
    Arch Int Pharmacodyn Ther; 1974 Oct; 211(2):211-24. PubMed ID: 4156639
    [No Abstract]   [Full Text] [Related]  

  • 13. MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats.
    Castellano JM; Batrynchuk J; Dolbeare K; Verma V; Mann A; Skoblenick KJ; Johnson RL; Mishra RK
    Peptides; 2007 Oct; 28(10):2009-15. PubMed ID: 17766011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of haloperidol-induced striatal dopamine receptor supersensitivity by active analogues of L-prolyl-L-leucyl-glycinamide (PLG).
    Rajakumar G; Naas F; Johnson RL; Chiu S; Yu KL; Mishra RK
    Peptides; 1987; 8(5):855-61. PubMed ID: 2893360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are the pharmacological effects of L-prolyl-L-leucyl-glycinamide (PLG) mediated through specific receptor mechanisms?
    Chiu S; Wong YW; Wan YP; Chiu P; Mishra RK
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):739-42. PubMed ID: 6141616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of dopamine receptor agonist-induced rotational behavior in 6-OHDA-lesioned rats by a peptidomimetic analogue of Pro-Leu-Gly-NH2 (PLG).
    Mishra RK; Marcotte ER; Chugh A; Barlas C; Whan D; Johnson RL
    Peptides; 1997; 18(8):1209-15. PubMed ID: 9396063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The action of prolyl-leucyl-glycinamide (PLG) on the nigrostriatal pathway of the rat.
    Pereira JS; Andrade LA; Bertolucci PH; Lima JG; Ferraz HB
    Arq Neuropsiquiatr; 1990 Jun; 48(2):156-60. PubMed ID: 1979732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesolimbic and striatal dopamine receptor supersensitivity: prophylactic and reversal effects of L-prolyl-L-leucyl-glycinamide (PLG).
    Chiu P; Rajakumar G; Chiu S; Johnson RL; Mishra RK
    Peptides; 1985; 6(2):179-83. PubMed ID: 2863809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison between a melanocyte-stimulating hormone inhibitory factor (MIF-I) and substances known to activate central dopamine receptors.
    Cox B; Kastin AJ; Schnieden H
    Eur J Pharmacol; 1976 Mar; 36(1):141-7. PubMed ID: 4332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of prolyl-leucyl-glycine (MIF-1) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on dopamine levels of the striatum].
    Sheng JG
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1989 Aug; 22(4):213-5, 253. PubMed ID: 2575971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.